Ginkgo Bioworks Holdings, Inc. (DNA) Cash Flow Statement
Ginkgo Bioworks Holdings, Inc. (DNA) generated -$170.2M of operating cash flow over the twelve months to 2026-06-30, spent $4.6M on capital expenditure and had free cash flow of -$174.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNAGinkgo Bioworks Holdings, Inc.Follow DNA — free
—
Price chart with a free account
- Market cap
- 672.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.25 | -0.25 | -0.30 | -0.32 | -0.17 | -0.17 | |
| Capital expenditure | 0.06 | 0.05 | 0.04 | 0.06 | 0.01 | -0.00 | |
| Free cash flow | -0.31 | -0.30 | -0.34 | -0.38 | -0.18 | -0.17 | |
| Stock-based compensation | 1.61 | 1.93 | 0.23 | 0.11 | 0.08 | — |
USD billions · SEC XBRL
Ginkgo Bioworks Holdings, Inc. — questions
- What is Ginkgo Bioworks Holdings, Inc.'s operating cash flow?
- -$170.2M over the twelve months to 2026-06-30.
- How much does Ginkgo Bioworks Holdings, Inc. spend on capital expenditure?
- $4.6M over the twelve months to 2026-06-30.
- What is Ginkgo Bioworks Holdings, Inc.'s free cash flow?
- -$174.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Ginkgo Bioworks Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.